Search
Descriptor English: Dactinomycin
Descriptor Spanish: Dactinomicina
Descriptor Portuguese: Dactinomicina
Descriptor French: Dactinomycine
Entry term(s): Actinomycin
Actinomycin D
Cosmegen
Cosmegen Lyovac
Lyovac Cosmegen
Lyovac, Cosmegen
Lyovac-Cosmegen
LyovacCosmegen
Meractinomycin
Tree number(s): D03.633.300.200
D04.345.566.252
D12.644.641.252
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D003609
Scope note: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Anti-Bacterial Agents
Antibiotics, Antineoplastic
Protein Synthesis Inhibitors
Nucleic Acid Synthesis Inhibitors
Registry Number: 1CC1JFE158
CAS Type 1 Name: Actinomycin D
Public MeSH Note: 66; ACTINOMYCIN was heading 1963-95
History Note: 66; ACTINOMYCIN was heading 1963-95
DeCS ID: 3628
Unique ID: D003609
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1966/01/01
Date of Entry: 1999/01/01
Revision Date: 2017/05/24
Dactinomycin - Preferred
Concept UI M0005644
Scope note A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Preferred term Dactinomycin
Entry term(s) Actinomycin D
Meractinomycin
Actinomycin - Broader
Concept UI M0005643
Preferred term Actinomycin
Cosmegen - Narrower
Concept UI M0354002
Preferred term Cosmegen
Entry term(s) Cosmegen Lyovac
Lyovac Cosmegen
Lyovac, Cosmegen
Lyovac-Cosmegen
LyovacCosmegen



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey